Everything below concerns LY3437943. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
In 1899 Lore Rogers was offered a position as assistant bacteriologist at the New York State Agricultural Experiment Station, Geneva. The New York State Legislature had established the State Agricultural Experiment Station, which opened in 1882. It was no coincidence that two bacteriologists overlapped at Wisconsin and arrived at the experiment station in 1899. Harry Alexis Harding had been an undergraduate and graduate student at Wisconsin under H. L. Russell (and would later earn a PhD at Cornell University). Harding, with his Wisconsin M.S. degree followed by study in Europe, was appointed chief dairy bacteriologist, and Lore would serve as assistant. The experiment station staff around 1900 included a superintendent, an animal industry specialist, two botanists, eight chemists, two bacteriologists, a dairy expert, three entomologists, three horticulturalists, an editor-librarian, and two clerk-stenographers. The two bacteriologists, Harry Harding, and Lore Rogers, collaborated on several reports on milk and cheese, with Harding listed as senior author. George A. Smith,"dairy expert" was another collaborator. Some station bulletins co-authored by Lore Rogers included "The Efficiency of a Continuous Pasteurizer at Different Temperatures" (1899), "Inspection of Babcock Milk Test Bottles" (1900), "Dairy Disagreeables Busy the Bacteriologists" (1900), and "Notes on Some Dairy Troubles" (1900).
=== Laboratory methods === In the laboratory, glycerol reacts with oxalic or formic acids to give (respectively) dioxalin or glyceric formate, either of which decarboxylate and dehydrate to allylol. Allyl alcohols in general are prepared by allylic oxidation of allyl compounds, using selenium dioxide or organic peroxides. Other methods include carbon-carbon bond-forming reactions such as the Prins reaction, the Morita-Baylis-Hillman reaction, or a variant of the Ramberg-Bäcklund reaction. Hydrogenation of enones is another route. Some of these methods are achieved by the Luche reduction, Wharton reaction, and the Mislow-Evans rearrangement. Allyl alcohol was first prepared in 1856 by Auguste Cahours and August Hofmann by hydrolysis of allyl iodide. Allyl alcohol can be formed by trituration of garlic (Allium sativum) cloves (producing from garlic in two ways: firstly by a self-condensation reaction of allicin and its decomposition products such as diallyl trisulphide and diallyl disulphide and secondly by the reaction between alliin, the precursor of allicin, and water). The compound's various connections with garlic give the allyl group its name (from Latin "allium" meaning garlic).
Some 3.3 V vaping devices using low-resistance heating elements such as an ohm of 1.5, containing 36 mg/mL liquid nicotine can obtain blood nicotine levels after 10 puffs that may be higher than with traditional cigarettes. A 2015 study evaluated "a variety of factors that can influence nicotine yield and found that increasing power output from 3 to 7.5 W (an approximately 2.5-fold increase), by increasing the voltage from 3.3 to 5.2 V, led to an approximately 4- to 5-fold increase in nicotine yield." A 2015 study, using a model to approximate indoor air workplace exposure, anticipates greatly reduced exposure to nicotine from e-cigarettes than traditional cigarettes. A 2016 World Health Organization (WHO) report found "nicotine in SHA [second-hand aerosol] has been found between 10 and 115 times higher than in background air levels." A 2015 Public Health England (PHE) report concluded that e-cigarettes "release negligible levels of nicotine into ambient air". A 2016 Surgeon General of the United States report stated that the exposure to nicotine from e-cigarette vaping is not negligible and is higher than in non-smoking environments. Vaping generates more surrounding air levels of particulate matter and nicotine in indoor areas than background air levels. Extended indoor e-cigarette use in rooms that are not sufficiently ventilated could surpass occupational exposure limits to the inhaled metals. The e-cigarette vapor may also contain tiny amounts of toxicants, carcinogens, and heavy metals.
Ia antiarrhythmic agents: A type Ia antiarrhythmic agent (see Vaughan Williams classification), i.e., procainamide, which is used to treat cardiac arrhythmias, has caused respiratory failure in people with myasthenia gravis who, prior to being treated with it, did not have respiratory symptoms. Furthermore, this drug has caused MG-like symptoms in people who have kidney failure but do not have myasthenia gravis. And, procainamide worsened muscle dysfunction in a rat model of human myasthenia gravis. Depolarizing neuromuscular blockers: Depolarizing neuromuscular blockers suppress the neurons' signaling at neuromuscular junctions thereby reducing the affected skeletal muscles contractibility. These blockers are used as muscle relaxants in people undergoing surgery. Succinylcholine is the only depolarizing neuromuscular blocker available in the US market. Succinylcholine's ability to induce or worsen myasthenia gravis is unclear. It has been suggested to cause life-threatening side effects such as rhabdomyolysis, myotonia, and hyperkalemia in people with muscle disease although the role of succinylcholine in causing these side effects also remains unclear. Inhalation anesthetics: Inhalation anesthetics are general anesthetics that are delivered by inhalation generally for people undergoing surgery.
1993/267) Local Government Act 1988 (Defined Activities) (Specified Period) (Woking Borough Council) Regulations 1993 (S.I. 1993/268) Education (Further Education Corporations) Order 1993 (S.I. 1993/269) Education (St Austell Sixth Form College and Mid-Cornwall College) (Dissolution) Order 1993 (S.I. 1993/270) St Austell College (Government) Regulations 1993 (S.I. 1993/271) Hereford and Worcester and Warwickshire (County Boundaries) Order 1993 (S.I. 1993/272) Housing and Planning Act 1986 (Commencement No. 18 and Transitional Provisions) (Scotland) Order 1993 (S.I. 1993/273) Environmental Protection Act 1990 (Commencement No. 13) Order 1993 (S.I. 1993/274) Planning and Compensation Act 1991 (Commencement No. 15) (Scotland) Order 1993 (S.I. 1993/275) River Tay Catchment Area Protection (Renewal) Order 1993 (S.I. 1993/276) Council Tax (Transitional Reduction Scheme) (Scotland) Regulations 1993 (S.I. 1993/277) Removal and Disposal of Vehicles (Amendment) Regulations 1993 (S.I. 1993/278) Guaranteed Minimum Pensions Increase Order 1993 (S.I. 1993/279) Social Security (Contributions) (Re-rating) Order 1993 (S.I. 1993/280) Social Security (Contributions) Amendment (No. 2) Regulations 1993 (S.I. 1993/281) Social Security (Contributions) Amendment (No. 3) Regulations 1993 (S.I. 1993/282) A63 Trunk Road (Selby Bypass) Order 1993 (S.I. 1993/286) A1041 Trunk Road (The Crescent to Brayton Lane) (De-trunking) Order 1993 (S.I. 1993/287) A63 Trunk Road (Whinny Hagg Lane to Magazine Road) (De-trunking) Order 1993 (S.I.
Sources: en.wikipedia.org
== Natural occurrence == DCA has been shown to occur in nature in at least one seaweed, Asparagopsis taxiformis and also in the mushroom Russula nigricans. It is a trace product of the chlorination of drinking water and is produced by the metabolism of various chlorine-containing drugs or chemicals. DCA is typically prepared by the reduction of trichloroacetic acid (TCA). DCA is prepared from chloral hydrate also by the reaction with calcium carbonate and sodium cyanide in water followed by acidifying with hydrochloric acid. As a laboratory reagent, both DCA and TCA are used as precipitants to prompt macromolecules such as proteins to precipitate out of solution.
==== Small RNA ==== At first, regulatory RNA was thought to be a eukaryotic phenomenon, a part of the explanation for why so much more transcription in higher organisms was seen than had been predicted. But as soon as researchers began to look for possible RNA regulators in bacteria, they turned up there as well, termed as small RNA (sRNA). Currently, the ubiquitous nature of systems of RNA regulation of genes has been discussed as support for the RNA World theory. There are indications that the enterobacterial sRNAs are involved in various cellular processes and seem to have significant role in stress responses such as membrane stress, starvation stress, phosphosugar stress and DNA damage. Also, it has been suggested that sRNAs have been evolved to have important role in stress responses because of their kinetic properties that allow for rapid response and stabilisation of the physiological state. Bacterial small RNAs generally act via antisense pairing with mRNA to down-regulate its translation, either by affecting stability or affecting cis-binding ability. Riboswitches have also been discovered. They are cis-acting regulatory RNA sequences acting allosterically. They change shape when they bind metabolites so that they gain or lose the ability to bind chromatin to regulate expression of genes.
== Mechanism == The first step involves a transfer of a coumaroyl moiety from a 4-coumaroyl-CoA starter molecule to Cys164. Next, a series of condensation reactions of three acetate units from malonyl-CoA occurs, each proceeding through an acetyl-CoA carbanion derived from malonyl-CoA decarboxylation. This extends the polyketide intermediate. After the generation of a thioester-linked tetraketide, a regiospecific C1, C6 Claisen condensation occurs, forming a new ring system to generate naringenin chalcone.
== Premise == One decade after most members of the Justice Society of America (JSA) are killed in battle against the Injustice Society of America (ISA), Courtney Whitmore, a high school student who moved to Blue Valley, discovers the Cosmic Staff of Starman and learns that her stepfather Pat Dugan used to be his sidekick. After encountering the remnants of the ISA which now include the mysterious Dragon King and his daughter Cindy Burman, Courtney becomes the inspiration for a whole new generation of superheroes and recruits Yolanda Montez, Rick Tyler, and Beth Chapel. In the second season, Stargirl and the JSA contend with the re-emergence of former ISA member Shade and a mysterious entity known as Eclipso, who works with Cindy to create a new ISA called Injustice Unlimited. When Eclipso breaks free from Cindy's control, the JSA works to stop him and finds new allies in Jennie-Lynn Scott, Jakeem Williams, Thunderbolt, a rescued Charles McNider, a revived Starman, and former ISA members Solomon Grundy, Sportsmaster, and Tigress. In the third and final season, the heroes and villains living in Blue Valley become embroiled in a murder mystery after former ISA member Steven Sharpe is found dead, while someone has been spying on them with cameras placed all over town. It turns out that a reconstituted Icicle was responsible as he is in league with the JSA's old enemy Ultra-Humanite and a surviving Dragon King.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.